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Abstract: Development is a complex process regulated both by genetic and epigenetic and environ-
mental clues. Recently, long non-coding RNAs (lncRNAs) have emerged as key regulators of gene
expression in several tissues including the brain. Altered expression of lncRNAs has been linked
to several neurodegenerative, neurodevelopmental and mental disorders. The identification and
characterization of lncRNAs that are deregulated or mutated in neurodevelopmental and mental
health diseases are fundamental to understanding the complex transcriptional processes in brain
function. Crucially, lncRNAs can be exploited as a novel target for treating neurological disorders. In
our review, we first summarize the recent advances in our understanding of lncRNA functions in the
context of cell biology and then discussing their association with selected neuronal development and
neurological disorders.
Keywords: long non-coding RNAs; neurodevelopment; neurological disorders; neurodegeneration;
neuropsychiatric disorders; Alzheimer’s disease (AZ); amyotrophic lateral sclerosis (ALS); autism
spectrum disorder (ASD); schizophrenia (SZ)
1. Introduction
For a long time, scientists believed that functional genetic information was only
contained in protein-coding genes. Proteins were considered the main protagonists in
cellular functions, while RNAs were thought to be mere intermediaries between DNA and
proteins [1].
In recent years, advances in genomic sequencing technology and findings from large-
scale consortia have facilitated our understanding of the mammalian genome’s complexity
and flexibility. Indeed, genome-wide analyses of the eukaryotic transcriptome have shown
that about 90% of the human genome is actually transcribed. Only about 2% of it is anno-
tated as protein-coding genes (ENCODE Project Consortium, https://encodeproject.org,
v117, accessed on 28 May 2021) [2], while the majority of transcripts represent non-coding
RNAs (ncRNAs) [3]. ncRNAs are a heterogeneous group of genes that do not have func-
tional open reading frames (ORFs) and are not transcribed into proteins. Due to these
biological characteristics, for a long time, they were considered “junk” [4,5]. Recent data
have shown that this part of the genome is functionally critical and is involved in phys-
iological processes and tissue homeostasis [6,7] both in health and disease [8–18]. This
has also been supported by the evolutionary analysis of conserved ncRNAs [8]. Indeed,
while the number of protein-coding genes has remained relatively stable, the number of
non-coding transcripts have increased considerably in parallel with the complexity of
organisms [19]. In this review, we discuss the diverse, general mechanisms of action of
well-studied lncRNAs and then focus on the role of lncRNAs in selected, primary examples
of neurodevelopmental and neurological disorders.
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1.1. Classification of ncRNAs
NcRNAs may be grouped into different classes and classified according to size and
function. In particular, ncRNAs are divided into two main classes: structural ncRNAs and
regulatory ncRNAs (Figure 1) [20]. The former are usually considered constitutive and
include ribosomal RNAs (rRNAs), transfer RNAs (tRNAs), small nuclear RNAs (snRNAs)
and small nucleolar RNAs (snoRNAs). Regulatory ncRNAs, on the other hand, are in turn
divided based on their length into three classes: short ncRNAs, which include microRNAs
(miRNAs, 22–23 nucleotides (nts)) and piwiRNAs (piRNAs, 26–31 nts); medium ncRNAs
(50–200 nts); and long ncRNAs (lncRNAs, > 200 nts) [21,22]. Most of these transcripts are
generated by post-transcriptional cleavage. These can be small or large RNA fragments,
which function independently from one another upon cleavage [23].
Figure 1. ncRNAs classes: schematic classification of ncRNAs into classes and sub-classes according
to their actions, biogenesis and structures (snoRNA: small nucleolar RNAs; tiRNA: transcription
initiation RNA; snRNA: small nuclear RNA; scRNA: small cytoplasmic RN; PROMPTs: promoter
upstream transcripts; rRNAs: ribosomal RNAs; tRNAs: transfer RNAs; miRNA: micro RNA; piRNA:
piwi RNA; siRNA: small interfering RNA; crasiRNA: centromere repeat-associated small inter-
acting RNA; telsRNA: telomere-specific small RNA; lincRNA: long intergenic noncoding RNA;
eRNA: enhancer-derived RNA; TUCRNA: transcribed ultraconserved RNA; NAT: natural antisense
transcript; cis-lncRNA: cis-acting long non-coding RNA; ceRNA: competing endogenous RNA;
trans-lncRNA: trans-acting long non-coding RNA).
1.2. Biogenesis of lncRNAs
A significant part of non-coding transcripts is represented by lncRNAs, which are RNA
transcripts longer than 200 nts. The biogenesis of lncRNAs resembles that of messenger
RNAs (mRNAs). They are transcribed by polymerase II (Pol II) and can be polyadenylated,
spliced and 5′-capped [7,21,23]. The mechanisms involved in the biogenesis of lncRNAs
are cell type-specific and controlled by stage-specific stimuli [20]. They undergo post-
transcriptional modifications and inter/intra-cellular transport. Most of them have different
expression patterns and preferentially nuclear localization, in contrast to mRNAs, because
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they are involved in chromatin and epigenetic regulation of gene expression [2,7,21,24].
Once transcribed, lncRNAs fold into a thermodynamically stable secondary structure.
RNA has the ability to form double helices, hairpins and pseudoknots thanks to high-level
tertiary interactions, mainly mediated by couplings of non-canonical bases. As shown in
Figure 2, four functional domains can be present in lncRNAs [25]:
A. RNA-binding domains. Thanks to their ability to base pair with other RNAs, lncR-
NAs can recognize and bind mRNAs, miRNAs and other lncRNAs, modulating
target levels and function;
B. Protein-binding domains. Proteins are a major partner of lncRNAs, forming ribonu-
cleoprotein complexes (RNPs) that act as chaperones, transport aids or effectors
(including phase-separation seeding). This type of interaction involves conforma-
tional changes in the protein, RNA or both;
C. DNA-binding domains. Currently, there is a lack of extensive evidence for direct and
functional interaction between lncRNAs and DNA as well as a lack of a consensus
regarding the role and function of these interactions. However, it is known that
RNA–DNA hybrids or triplex structures can allow single strands of RNA to interact
with DNA duplexes through pair–base interactions. These direct interactions can
efficiently and selectively direct RNA signals to genomic loci through base-pairing
interactions. However, such interactions can also expose the genome to deamination
and damage;
D. Conformational switch. LncRNAs can act as regulatory devices by allosterically cou-
pling binding domains with the switching of structural conformations and thereby
activating or suppressing linked functional domains.
Figure 2. Domain architecture of lncRNAs. Schematic representation of lncRNAs’ structural domains,
through which they can bind other RNAs via complementary base–pair interactions (A), proteins (B)
and DNA (C). These interactions can induce allosteric, conformational changes to other structures in
the lncRNA (D).
1.3. Types of lncRNAs
LncRNAs can be classified based on their biogenesis, structure, localization or mecha-
nism of action [20,26,27]. Based on their localization in the genome compared to protein-
coding genes, they can be further divided into various subclasses (Figure 3) [28]:
Non-coding RNA 2021, 7, 36 4 of 25
A. Sense lncRNAs, which overlap one or more exons of neighboring mRNAs on the
same strand; antisense lncRNAs, which overlap one or more exons of neighboring
mRNAs on the opposite strand; intronic lncRNAs, which are transcribed from introns
of a second transcript (sometimes may represent pre-mRNA sequences);
B. Promoter upstream lncRNAs, which are located upstream of a promoter; promoter-
associated lncRNAs, which are close to the promoter;
C. Intergenic lncRNAs, which lie within the genomic interval between two genes;
D. Bidirectional lncRNAs, which have promoters in common with protein-encoding
genes but are transcribed in the opposite direction; 3′UTR-associated lncRNAs,
which are transcribed from a protein-coding gene’s 3′UTR region.
Figure 3. Classification of lncRNAs. (A) Sense lncRNAs and antisense lncRNAs are, respectively, present on the same
and opposite strands and overlap with neighboring mRNAs; intronic lncRNAs are transcribed from the introns of the
protein-coding genes. (B) Promoter upstream lncRNAs are located upstream of the promoter; promoter-associated lncRNAs
are close to the promoter. (C) Intergenic lncRNAs are transcribed from the genomic interval between two genes. (D)
Bidirectional lncRNAs have transcription start sites that are close to adjacent genes on the antisense strand, and these have
common promoters; 3′UTR-associated lncRNAs are obtained from a protein-coding gene’s 3′UTR region.
Another approach in the classification of lncRNAs is based on their subcellular
localization, which can be linked to their function (such as chromatin-associated lncR-
NAs, chromatin-interlinking RNAs, nuclear bodies-associated RNAs and PRC2-associated
RNAs [29]) or to their structure, distinguishing linear lncRNAs from the circular lncRNAs
(circRNAs that are produced in a process called “back-splicing” [30].
Finally, based on the mode of action, lncRNAs can be divided into cis-acting lncRNAs,
trans-acting lncRNAs (i.e., working on the same chromosome they are transcribed for, or
not, respectively) and competing endogenous lncRNAs, which share sequence and function
similarities with mRNAs and compete with them for function [20,29].
1.4. Evolution, Conservation and Stability of lncRNAs
Comparing lncRNAs with protein-coding genes and small ncRNAs, lncRNAs were
found to be poorly conserved at the primary structure level (i.e., sequence conservation).
In fact, for protein-coding genes, the average number of nucleotide substitutions is ap-
proximately 10%, while for lncRNAs, this number increases up to 90–95%, thus estimating
that only 5–10% of the sequences are preserved [31]. A noticeable example is Xist, the
lncRNA involved in the inactivation of one of the two X chromosomes in mammalian
females, which appears to be relatively poorly conserved in some eutherians’ clades [32].
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Multidisciplinary studies have, however, highlighted how regions such as the promoter
and the exon–intron boundaries are much more conserved in lncRNAs sequence [33].
Furthermore, in a recent work, Kirk and colleagues [34] developed the SEEKR (sequence
evaluation through k-mer representation) method, which allows quantifying the similarity
of nonlinear sequences between lncRNAs by evaluating all possible sequence combinations
at a given length (k) within the lncRNA. In this way, it is possible to expand the number
of significant correlations with protein binding and lncRNA subcellular localization. For
example, substantial levels of nonlinear sequence similarity were found between functional
domains in Xist and domains in the Rsx lncRNA, a marsupial lncRNA originating from
convergent evolution that has been proposed as a functional analogue of Xist [35,36]. There-
fore, k-mer represents a promising approach for the functional classification of lncRNAs
based on their sequence [36].
Sequence analysis and experimental investigation also allowed obtaining information
on the lncRNAs’ secondary structure. LncRNA secondary structures are characterized
by modular structures, organized in independent RNA modules with different functions.
Each domain contains several structural motifs such as internal and terminal loops as well
as helices and junction regions regulating its function. [37]. To date, few lncRNAs have
been characterized at the secondary structure level including Xist [37–41], HOTAIR [37,42],
lincRNA-p21 [37,43] and several others. For instance, HOTAIR consists of four independent
domains containing 56 helical segments, 38 terminal loops, 34 internal loops and 19 junction
regions [37,42]; Xist is characterized by different conserved regions of tandem repeats,
which are indispensable for specific functions [44]. For example, its 5′ region is highly
conserved and consists of 8.5 copies in humans (7.5 in mice) of 26-mers separated by U-rich
linkers (A-repeat) that assume double stem–loop structure ensembles, which function as a
platform for the protein binding involved in gene silencing [44]. All these structures can
undergo rearrangements due to polymorphisms or post-transcriptional modifications that
alter their stability. It is therefore deduced that lncRNAs do not strictly have a conserved
primary structure but maintain conserved functions that are carried out through the
promoter regions, splicing patterns, expression patterns and secondary structure through
interaction with RNA-binding proteins [26,45].
Stability is an important feature for the functional analysis of lncRNAs. It is, in fact,
known that the average half-life of each RNA is related to its physiological function.
LncRNAs have a much shorter half-life and greater variability than mRNAs. In particular,
it is possible to divide lncRNAs into unstable (average half-life < 2 h), stable (average
half-life > 2 h) and extremely stable (average half-life > 16 h). Furthermore, intergenic
and antisense lncRNAs are more stable than intronic ones, just as the transcripts that have
undergone splicing are more stable than those that have not undergone it (single exon).
Finally, nuclear lncRNAs are probably more unstable than others with different subcellular
locations [46].
2. Functional Roles of lncRNA in Cellular Processes
LncRNAs are dynamically expressed during cell differentiation and development.
They are able to regulate the cell cycle, genetic imprinting and stem cell reprogram-
ming [26,45–51]. An increasing number of lncRNAs are specifically expressed during brain
development as well as neural stem cell and progenitor differentiation. Some examples
are MALAT1 (metastasis-associated lung adenocarcinoma transcript 1), which regulates
synaptogenesis, and Sox2OT (Sox2 overlapping transcript), which overlaps the Sox2 gene
encoding for a transcription factor important for neural stem cell self-renewal [52]. LncR-
NAs play a key role in the development and onset of several related neuropathologies such
as Down syndrome, Rett syndrome, Fragile X syndrome and autism spectrum disorders,
wherein abnormal expression of lncRNAs affects neurodevelopment and plays a major role
in pathogenesis [3,52–57].
The main biological functions of lncRNAs include epigenetic regulation, chromatin
remodeling and protein metabolism control. They can act at the transcriptional and post-
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transcriptional level, in cis or trans, and also act as a signaling molecule with a scaffolding
role [20,28,50]. By definition, lncRNAs are different from coding mRNAs because they lack
a substantial ORF and fail to produce proteins [26,58–60]. However, recent evidence has
shown that some annotated lncRNAs can actually encode small functional peptides [61].
In addition, a recent analysis by Ruiz-Orera and colleagues [62] on ribosome profiling
experiments provided important evidence that lncRNAs associated with ribosomes might
play an important role in de novo protein evolution by encoding short peptides. The role
of these peptides is not yet known and if they are functional. It is therefore believed that
exploring the pathological and physiological effects of the new peptides generated by
lncRNAs can unlock new fields of investigation.
2.1. Mechanisms of Action
LncRNAs are very versatile molecules that have the ability to create physical and
functional interactions with DNA, RNA and proteins through base pairing or through
functional domains, which are generated thanks to their secondary and tertiary folding
(discussed above) [63].
LncRNAs can regulate gene expression positively or negatively through multiple
mechanisms. Many lncRNAs act via chromatin modulation by working as molecular
scaffolds for protein–protein interactions or interacting with chromatin-modifying com-
plexes and recruiting chromatin-modifying complexes at specific loci to activate or repress
target gene expression [64,65]. Some lncRNAs affect transcription by modulating the bind-
ing of the general transcription machinery and regulatory factors [4,29,65–67]. They are
involved in RNA processing [65,68], RNA turnover, silencing, translation and decay of
mRNAs [49,65,69,70] or act as miRNA sponges to neutralize miRNA-mediated mRNA
silencing [65,71]. In addition, some lncRNAs are determined to be precursors of certain
miRNAs at particular stages of development [30,65].
The function of lncRNAs also depends on their subcellular localization. They can
localize in different cellular compartments including the nucleus, the chromatin and the
cytoplasm based on sequence and structural motifs [72]. For example, the AGCCC motif
is strongly correlated with lncRNAs nuclear localization [73]. Therefore, more and more
resources have been spent on the design of tools that allow predicting lncRNAs sub-cellular
location using nucleotide compositions [72,74]. Many are important modulators for nuclear
functions. Several lncRNAs act in cis on their transcription sites. In this way, they manage to
modulate local gene expression, both by recruiting transcription factors and/or chromatin
modifiers and might be forming a DNA–RNA triplex that anchors lncRNA and the effector
proteins associated with the gene promoter [20]. Others need to be relocated from their
synthesis sites while maintaining nuclear localization. They, therefore, act in trans to have
an impact on gene regulation. Finally, other lncRNAs must be exported to the cytoplasm to
play their regulatory roles, interfering with post-translational modifications or influencing
gene regulation by acting as decoys for miRNAs and proteins [20,28,50].
2.2. LncRNAs as Chromatin Regulators
LncRNAs are involved in global epigenetic reprogramming during cell growth and
development. Within the nucleus, they can affect chromatin status through inter- and intra-
chromosome interactions, remodeling chromatin and its condensation by acting on specific
chromatin loci and regulating gene expression through mechanisms such as methylation
or acetylation without changing the DNA sequence. Additionally, lncRNAs influence
chromosome bridging by binding to heterogeneous nuclear ribonucleoprotein U [3,5,28,64].
A fraction of lncRNAs bind to the Polycomb repressive complex 1/2 (PRC1/2) [75] or the
chromatin-modifying proteins CoREST and SMCX [76]; others bind to trithorax chromatin-
activating complexes (trxG) [77]. These complexes act as antagonists in gene expression
regulation during cell development and differentiation. In particular, while the PRC2
complex plays a role in repressive histone modifications, trxG promotes the transcriptional
activation of Hox genes [78,79].
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The well-characterized lncRNAs HOTAIR, ANRIL, XIST and KCNQ1OT1 are able to
recruit epigenetic modifiers to specific loci for reprogramming the chromatin state [64,80].
For example, HOTAIR acts as a scaffold for coordinating the targeting of specific repressive,
histone-modifying complexes to target loci [80]; XIST mediates X chromosome inactivation
by recruiting repressive histone complexes such as PRC1 and PRC2 [81–83] and DNA-
methylating complex [84]. Additionally, lncRNAs affect allelic gene expression through im-
printing. Gene expression is regulated by specific genomic loci where protein-coding genes
and lncRNAs are reciprocally expressed (Nesp/Nespas, Igf2r/Air, Dlk1/Gtl2). Moreover,
some lncRNAs in specific loci may also control the imprinting regulation of neighboring
genes via additional epigenetic factors [7].
2.3. Transcriptional, Post-Transcriptional and Post-Translational Regulation
The regulation of transcription by lncRNAs is mediated through chromatin regulation
and various transcription factors (TFs), modifying lncRNAs activity and/or binding [28,49,64].
In particular, some lncRNAs regulate transcription via competing for TFs or recruiting TFs
acting as either co-activators or co-repressors of specific genes [7,28,49,85–88]; others lncR-
NAs directly act on RNA polymerase II by interacting with the initiation complex [89,90].
LncRNAs play a key role also in post-transcriptional events such as mRNA splicing,
editing, transport, translation and degradation [28,30,64]. For instance, several nuclear lncR-
NAs including NEAT1, MALAT1, MIAT (also known as GOMAFU) and SAF were linked to
splicing regulation. They recognized splicing factors and influenced their activity by either
modulating their post-translational modifications (e.g., phosphorylation) or by regulating
interactions with other splicing factors and with protein-coding mRNAs [19,91–94]. Fur-
thermore, lncRNAs can be implicated in alternative splicing through lncRNA-mediated
chromatin remodeling [92,93]. For example, MIAT binds splicing factor 1 (SF1) protein
through its UACUAAC repeat sequences and inhibits splicing and spliceosomal complex
formation [95]; MALAT1 regulates the alternative splicing of endogenous target genes
through the modulation of the phosphorylation status of splicing factors [68,96].
LncRNAs can also regulate RNA levels. Some of them can alter their stability by
acting on the 3′UTR regions rich in AU elements, with consequences for transcript degra-
dation, decapping and deacetylation [7,49,69]; others such as BACE1AS can act to form an
RNA–RNA duplex, increasing the stability of the mRNA [7,49,97].
LncRNAs can also act as scaffolds for higher-order complexes. For examples, lncR-
NAs can organize translational particles during ribosome translation in the endoplasmic
reticulum (ER) [36] and to mediate stress granule formation through RNA–RNA interac-
tions [5]. Finally, they can interact synergistically with mRNAs and act as miRNA inhibitory
regulators modulating target expression [28,30,64,98–100].
Finally, lncRNAs play a role in the post-translational modifications of proteins in-
cluding phosphorylation, ubiquitination and acetylation. Therefore, they regulate protein
formation, degradation and expression [101]. For example, in cancer, the lncRNAs HULC
promotes cell proliferation through activation of the ERK pathway, with consequent phos-
phorylation of YB-1 preventing its interaction with other oncogenic mRNAs [102].
3. LncRNAs in Neurological and Neurodegenerative Disorders
LncRNAs are involved in the cell differentiation and function of all cell lineages. Given
the many functions of lncRNAs, it is important to understand that any mutation resulting
in either gain- or loss-of-function can have a major impact on protein synthesis, metabolism
and many other cellular activities. In this review, we will focus on selected examples of
neurological and neurodevelopmental disorders (see below).
Several pieces of evidence have shown that lncRNAs dysregulation is related to var-
ious neurological disorders including neurodegenerative diseases and neuropsychiatric
disorders [50,65]. Neurodegenerative disorders are characterized by progressive neuron
dysfunction and/or degeneration, affecting the nervous system functionality. The con-
sequent clinical symptoms, both motor and cognitive, vary and are characteristic of the
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specific disorder. Moreover, neurodegenerative disorders can be age-related or non-age-
related and sex-biased and be either familiar or sporadic [4,26,31,103,104]. LncRNAs play a
significant role in the pathophysiology of these disorders due to their important regulatory
functions within the cell, involvement in various signalling pathways and the functioning
of mitochondria; hence, their dysregulation may lead to the death of neurons and brain
atrophy (Table 1) [26,105,106]. Therefore, it is crucial to expand our knowledge on the
lncRNAs involved in the pathophysiology of these diseases and their mechanisms of action.
In this way, we will be able to gain a better understanding of the processes underlying
neurological diseases (for example, the signaling pathways involved) in order to create
better diagnostic tools and new forms of treatments [106].
Table 1. LncRNAs dysregulated in neurodegenerative disorders. The chosen examples of lncRNAs involved in neurodegen-





BACE1-AS enhances mRNA BACE1 stability
and activity. Leads to Aβ formation through
the amyloid pathway.
AD Faghihi et al., 2008 [97];Faghihi et al., 2010 [71]
51A UP
51A upregulates SORL1 variant A, which
leads to Aβ accumulation through altered
amyloid processing.
AD
Ma et al., 2009 [107];
Ciarlo et al., 2013 [108];
Luo and Chen 2016 [109]
17A UP
17A disrupts GABAergic signalling (through
the inhibition of GABAB R2 activity). This
leads to an inflammation response and
upregulation of Aβ formation and increases
the Aβx-42/Aβx-40 ratio.
AD
Massone et al., 2011 [110];
Gavazzo et al., 2013 [111];
Buggia-Prevot and Thinakaran, 2014 [112]
NDM29 UP
NDM29 promotes the cleavage activity of
γ-secretase and BACE1 secretase, increasing the
production of Aβ formation and the Aβx-42/
Aβx-40 ratio. Moreover, it triggers an
inflammatory response.
AD Massone et al., 2012 [113]
BC200 UP
BC200 takes part in the maintenance of
long-term synaptic plasticity by targeting
eIF4A and interacting with local proteins. In
AD, it leads to the increased loss of synapses.
AD Mus et al., 2007 [114];Lin et al., 2008 [115]
NAT-Rad18 UP NAT-Rad18 increases the cell death rate inneurons, promoting the apoptotic processes. AD
Iacoangeli et al., 2010 [116];
Massone et al., 2012 [113];
Luo and Chen, 2016 [109]
NEAT1
UP/DOWN NEAT1 is involved in the decreasedclearance of Aβ. AD
Wang et al., 2019 [117];
Zhao et al., 2019 [118];
UP NEAT1 regulates the assembly of paraspecklesand might trigger neurotoxic processes in ALS. ALS
Clemson et al., 2009 [119];
Suzuki et al., 2019 [120]
MALAT1 UP
MALAT1 facilitates paraspeckle formation by
binding with FUS and TDP-43. Moreover, it
controls the phosphorylation of SR proteins
and gene expression in cis.
ALS
Clark et al., 2014 [50];
An et al., 2019 [121];
Wu and Kuo, 2020 [106]
C9ORF72 UP
C9ORF72 extended repeats mutation leads to
the repeat-associated translation into neurotoxic
misfolded proteins and dipeptides. Contributes
to the SGs’ formation and cellular inclusions.
ALS
Mizielinska et al., 2014 [122];
Wen et al., 2014 [123];
Maharjan et al., 2017 [124];
Wan et al., 2017 [29];
Swinnen et al., 2018 [125]
Bampton et al., 2020 [126]
Mizielinska et al., 2013 [127]
SATIII(Hsrω) UP
SAT III binds to TDP-43 and takes part in
promoting its elongation (by binding to the
ELL2 domain) during the transcription, which
can affect TDP-43 neurotoxicity.
ALS
Chung et al., 2018 [128];
Chen, K. and Chen, 2020 [5];
Wu, et al., 2020 [106]
ATXN2-AS DOWN
ATXN1-AS extended repeats form RNA foci
and lead to an increase in apoptosis through
interactions with caspase 3/7.
ALS Li et al., 2016 [129]
SNAP25-AS DOWN
SNAP25AS affects SNAP25 and processes
controlled by it such as synaptic vesicle
transport or axonal repair processes.
ALS Gagliardi et al., 2018 [130];Wu et al., 2020 [106]
Non-coding RNA 2021, 7, 36 9 of 25
For this review, we selected noticeable examples of lncRNA role in diseases such
as Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). Finally, as prime
examples of defective neurodevelopment, we chose to discuss the role of lncRNA in
schizophrenia (SZ) and autism (ASD).
3.1. Alzheimer’s Disease
AD is one of the most prevalent aging-related neurodegenerative diseases and causes
of dementia worldwide [109,131,132]. This disease is characterized by progressive degen-
eration of cortical neurons, leading to brain tissue atrophy and clinical symptoms such as
dementia and cognitive decline. The two main characteristics of AD are the accumulation
of amyloid-beta (Aβ) in the extracellular senile plaques and hyperphosphorylated tau
protein in the intracellular neurofibrillary tangles [26,106,131–134]. However, several other
factors can cause neurodegeneration such as neuroinflammation and oxidative stress [131].
AD is a multifactorial disease associated with several risk factors. It has a strong
genetic component, with mutations in genes responsible for Aβ processing linked to the
pathophysiology of this disease. Research from recent years has shown that lncRNAs play
a major role in AD through epigenetic control of target genes (Table 1) [135–138]. Studies
evaluating the profiles of aberrantly expressed transcripts in AD animal models showed
that most of the lncRNAs upregulated or downregulated in AD were linked to metabolic
pathways (in some cases, through insulin signalling), inflammatory processes and also
synaptic transmission [136,139]. Interestingly, some lncRNAs that are dysregulated in
AD have an opposite expression profile in cancer. For instance, the transcripts linked to
neurodegeneration that are downregulated in AD are instead upregulated in cancer and
involved in processes associated with the survival and proliferation of cancer cells [136,140].
One of the best-studied lncRNAs transcripts to date is BACE1-AS (Table 1), which
is the antisense transcript to the gene encoding beta-secretase 1 (BACE1), which is in-
volved in the amyloid pathway of Aβ cleavage. In particular, the enzyme encoded by
BACE1 is responsible for the cleavage of the amyloid precursor protein (APP). BACE1
overexpression results in the increased synthesis of the misfolded protein. Therefore,
BACE1 levels can be used as a blood plasma biomarker for brain amyloidosis in people
with AD [137,141]. BACE1-AS expression upregulates the transcription of BACE1 mRNA
through the formation of stabilizing RNA duplex by binding to the open reading frame
of BACE1 and masking the miRNA-485-5p binding site [71,97]. This event can trigger an
increase of both BACE1 mRNA and protein levels, leading to enhanced Aβ formation
(Figure 4) [118,142–144]. Finally, BACE1-AS can decrease the level of miR-132-3p, which
plays an important role in synaptic plasticity and activation [106,143].
BC200 (brain cytoplasmic 200 RNA) (Table 1) is responsible for the synthesis of den-
dritic neural proteins and for long-term synaptic plasticity regulation by targeting eu-
karyotic initiation factor 4A (eIF4A). In AD, this transcript becomes upregulated with
aging and disease progression with consequent alteration to the regulation of synap-
tic and dendritic transport through the microtubules, which leads to their degenera-
tion [26,106,109,113,114,145].
Another interesting example of lncRNA linked to AD pathophysiology is the product
of the sortilin receptor 1′s (SORL1) first intron, regulated byalternative splicing (51A)
(Table 1). It has been reported that in AD patients, 51A is upregulated, along with the
lower level of SORL1 expression. 51A regulates the alternative splicing of SORL1 mRNA,
downregulating the production of the canonical variant of this receptor. These events
can drive AD pathophysiology, as SORL1 has a neuroprotective property by binding to
apolipoprotein E (APOE), which interacts with Aβ, reducing APP oligomerization in the
BACE1 amyloid pathway [109,142,146–148].
LncRNA E230001N04Rik has been shown to regulate tau aggregates production in AD
in the okadaic-acid induced in vitro AD model. This happens due to the upregulation of
E230001N04Rik lncRNA’s neighboring genes, which are responsible for tau’s production
(Sepk1), stability and aggregation (Fkbp5). Both of these genes are upregulated in AD
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patients. Moreover, the KD of this lncRNA in the HT22 cell line resulted in significantly
lower tau production compared to the control [136].
Figure 4. BACE1-AS involvement in AD pathophysiology. The BACE1-AS locus is localized on
chromosome 11 (www.genecards.org, accessed on 28 April 2021). Its product binds to BACE1,
stabilizing this mRNA and masking a binding place for miR485-5p, which normally inhibits the
BACE1 enzyme translation. In this way, BACE1 leads APP into the amyloid pathway, increasing the
production of the Aβ aggregates into the amyloid plaques.
LncRNAs BDNF-AS and GDNF-OS are, respectively, the antisense transcripts of brain-
derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF).
They both negatively regulate neurotrophic factor expression, promoting the pathogenesis
of AD. In fact, low levels of BDNF and GDNF cause a minor neuroprotective effect against
Aβ accumulation [29,149,150].
3.2. Amyotrophic Lateral Sclerosis (ALS)
ALS, also known as motor neuron disease (MND), is a severe neurodegenerative disor-
der that is not related to natural aging [151–154]. The progressive degeneration of neurons
in ALS is observed in both upper and lower motor neurons. Depending on the affected
region of the nervous system, ALS can result in various clinical symptoms, inevitably
leading to muscle paralysis. The exact etiology is still unknown, and its pathophysiology
can be quite diverse and involves mitochondrial dysfunction, the defective metabolism
of RNA, disrupted axonal transport and misfolded protein aggregation [29,106,153,154].
As ALS has such diverse pathophysiology, there are still a lot of unknown mechanisms
that may be driving its pathophysiology. LncRNAs have already been shown to play an
important role in many of these mechanisms, especially in intracellular inclusion formation,
which is a hallmark of ALS (Table 1) [106,155]. Some of these inclusions are stress granules
(SGs) located in the endoplasmic reticulum; others are nuclear bodies (NBs) within the
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nucleus [49,156]. All of them are membranelle structures composed of RNAs and proteins,
the formation of which takes place through liquid–liquid phase separation (LLPS) and is
controlled by lncRNAs and RNA-binding proteins [156,157]. LLPS in healthy conditions is
a reversible process wherein RNA low complexity domains, proteins and heterogeneous
nuclear ribonucleoproteins interact and bind, forming droplet-like structures within the en-
vironment with liquid-like properties [126]. These structures are involved in homeostasis,
but in ALS, due to increased cellular stress, they do not dissolve and lead to neurotoxicity.
One of the key lncRNAs involved in their formation through LLPS is NEAT1 (nuclear
enriched abundant transcript 1) (Table 1), which regulates both SGs’ and NBs’ assembly
and dynamics (Figure 5) [119,121,156,158,159]. NEAT1 is most predominantly present in
two forms: NEAT1_1, which regulates transcription by chromatin activation and NEAT1_2,
which regulates the formation of paraspeckles (nuclear RNA granules formed through
liquid–liquid phase separation). This second form is linked to ALS susceptibility [20,121].
In fact, in healthy mammals, generally NEAT1_2 is not expressed, whereas in ALS patients,
its level is increased. It can be found especially in the anterior horn of the spinal cord,
leading to paraspeckle formation and further degeneration due to neurotoxicity [120,121].
Furthermore, NEAT1 has been linked to the accumulation of misfolded TAR DNA-binding
protein 43 (TDP-43) in intracellular inclusions. There is, in fact, a clear co-localization
and binding of NEAT1 and TDP-43 in cellular stress conditions, which can be found in
cellular inclusions in some ALS cases [156]. Moreover, the same feature also underlies the
pathophysiology of frontotemporal dementia (FTD), which is very often comorbid with
ALS [106,151].
C9ORF72 is another example of an lncRNA associated with ALS (Table 1). It interacts
with Rab proteins and controls endocytosis, autophagy and SG clearance. In ALS patients, it
shows a significantly expanded number (>30) of GGGGCC repeats between 1a and 2b exons.
After this transcript is translated, the protein loses its physiological function, which in
healthy conditions, is linked to the regulation of endocytosis and autophagy [151,160,161].
Moreover, the extended number of hexanucleotide repeats of the sense and antisense RNA
can co-localize with proteins involved in SGs formation, which is neurotoxic and leads to
neurodegeneration (Figure 6) [124,158,162]. Additionally, the pathological repeats can be
further translated into misfolded proteins, binding into toxic aggregates that can be found
in the brain stem and spinal cord of some patients [158,163]. Finally, the repeat expansion
can form a G-quadruplex structure that functions as a platform to recruit proteins such as
TDP-43 and p62, forming pathological neuronal cytoplasmic inclusions [127]. C9ORF72
can additionally undergo LLPS by forming droplet-like cellular inclusions [126,164].
Sat III (stress-induced satellite III repeat RNA) encodes for another lncRNA over-
expressed in ALS (Table 1). Some studies of its functional orthologue in Drosophila
melanogaster, Hsrω, showed that this transcript bound the protein dFUS, which was in-
volved in ALS pathogenesis and could also be present in toxic cellular inclusions containing
aggregated proteins [128,165]. The knockdown of this lncRNA led to dFUS translocation
to the cytoplasm, altering the functioning of the protein [126,164]. Furthermore, Hsrω was
also linked to TDP-43 aggregates formation, as it enhanced the expression of the gene
encoding for this protein [166].
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Figure 5. NEAT1 in paraspeckle formation. (A) The NEAT1 locus is localized on chromosome 11
(www.genecards.org, accessed on 28 April 2021). (B) NEAT1 can be transcribed by the RNAPII into
NEAT_1 or NEAT_2 transcripts, which vary in the structure of their 3′ end. The dot at the 5′ end of
each variant represents the structure of a cap. The triple helix and tRNA-like structure at the 3′-end
of NEAT1_2 prevent the polyadenylation at the 3′-end of this isoform. HNRNPK (heterogeneous
nuclear ribonucleoprotein K) is a crucial factor for NEAT1_2 processing, as it prevents NEAT1_1
polyadenylation, which is dependent on SPSF5/6. NEAT1_2 additionally binds stabilizing PLD
(phospholipase D)-containing, RNA-binding proteins such as NONO (non-POU domain-containing,
octamer-binding protein), SFPQ (splicing factor, proline- and glutamine = rich) or RBM14 (RNA
binding protein 14). The NEAT1 lncRNA is localized into the cellular inclusions along with SWI/SNF
(SWItch/sucrose non-fermentable) complexes (made out of grouped stabilizing, PLD-containing
proteins) and FUS and other PLD-containing proteins.
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Figure 6. C9ORF72’s role in ALS pathophysiology. (A) The C9ORF72 locus is localized on chromo-
some 9 (www.genecards.org, accessed on 28 April 2021). (B) In ALS patients, in C9ORF72, there
have been observed a significantly extended number (>30) of GGGGCC repeats in the gene. (C) This
mutation leads to impaired translation of the protein and its loss of function (LOF). (D) The sense and
the antisense transcripts bind to RNA-binding proteins (RBP) forming nuclear foci and forming toxic
aggregates (GOF: gain of function), which affects cellular processes such as splicing, transcription and
nucleocytoplasmic transport and leads to nuclear stress (E,F). These transcripts are further translated
into misfolded proteins, which can form toxic dipeptide aggregates (GOF). All the toxic cellular
inclusions lead to cellular stress and eventually cell death (GA: glycine–alanine; GP: glycine–proline;
GR: glycine-arginine; PA: proline–alanine; PR: proline–arginine; GP: glycine–proline).
4. LncRNAs in Neurodevelopmental and Neuropsychiatric Disorders
LncRNAs play a key role in neurogenesis, synaptogenesis and brain development.
Thanks to high-throughput technologies, it is clear that they are expressed in specific
cell types, subcellular compartments and different regions of the brain [167,168]. Many
lncRNAs are expressed in an age-dependent manner [169] and participate in neural cell
fate determination [65]. Because of their involvement in these processes, any aberrant
expression of these transcripts may result in neurodevelopmental or neuropsychiatric
disorders such as autism spectrum disorder (ASD) or schizophrenia (SZ), among many
others (Table 2) [65,170]. During neurodevelopment and brain functioning, GABAergic
transmission is fundamental. Studies have shown that disrupted functions of GABAer-
gic interneurons and associated lncRNAs can be observed in both ASD and SZ [170].
LncRNAs are also involved in many other genetic syndromes resulting in altered neurode-
velopment including Angelman syndrome, Rett syndrome, fragile X chromosome and
Down syndrome, which are linked with a predisposition to intellectual disability and ASD
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features [52–57,170,171]. Moreover, some of these syndromes can be comorbid with other
neurodevelopmental disorders, suggesting that they may share pathophysiology and some
molecular pathways [170,171].
Table 2. LncRNAs dysregulated in neurodevelopmental and neuropsychiatric disorders. The chosen examples of lncRNAs
are involved in neurodevelopmental and neuropsychiatric disorders. (UP: upregulation; DOWN: downregulation; references
are shown).
LncRNA ExpressionChange Role Linked Disorder References
GOMAFU DOWN
GOMAFU controls alternative splicing through
interactions with splicing factors. Moreover, it
affects the specification of amacrine cells and is
involved in SZ-related eye movement disorder.
SZ
Takahashi et al., 2003 [172];
Rapicavoli et al., 2010 [173];
Tsuiji et al., 2011 [95];
Ip et al., 2016 [174]
MALAT1 DOWN
MALAT1 controls the expression of genes
linked to synaptogenesis through interactions
with SR proteins. The downregulation of
MALAT1 leads to impaired formation of
synapses and reduced synaptic density.
SZ Bernard et al., 2010 [175];Madabhushi et al., 2015 [176]
DISC1-AS DOWN DISC1-AS affects cAMP signaling throughinteractions with DISC1 and DISC2. SZ
Millar et al., 2004 [177];
Chubb et al., 2008 [178]
DISC2-AS DOWN
DISC2-AS affects cAMP signaling (through
interactions with DISC2), neuregulin signalling,
axonal signalling and also long-term synaptic
potentiation.
SZ Polesskaya et al., 2003 [179];Walsh et al., 2008 [180]
NEAT1 DOWN NEAT1 takes part in the unfolded proteins’response under a condition of cellular stress. SZ
Nakagawa et al., 2011 [181];
Hirose et al., 2014 [182]
SHANK2-AS DOWN
SHANK2-AS affects the processes regulating
post-synaptic density through interactions
with SHANK2.
ASD Wang et al., 2015 [183]
BDNF-AS DOWN
BDNF-AS inhibits the BDNF transcript, which
is a crucial transcription factor involved in
neurite functioning.
ASD Wang et al., 2015 [183]
PTCHD1AS1-3 DOWN PTCHD1AS1-3 is linked to the dysfunctionof synapses and neurons in ASD. ASD Noor et al., 2010 [184]
NRON UP NRON inhibits NFAT (nuclear factor-activatedT-cell) signaling. Major Depressive Disorder Willingham et al., 2005 [85]
AK081227 UP AK081227 downregulates GABAergic signallingthrough the inhibition of Gabrr2 expression. Rett Syndrome Petazzi et al., 2013 [54]
Ube3aATS DOWN
Ube3aATS downregulation is associated with
impaired contextual fear behavior (in Angelman
syndrome). This is due to the impaired silencing of
paternal Ube3a.
Angelman Syndrome
Meng et al., 2012 [185];
Meng et al., 2013 [186];
Meng et al., 2015 [187]
4.1. Autism Spectrum Disorder
ASD is a heterogeneous neurodevelopmental disorder that arises from defects and
aberrant gene expression during development. Its clinical symptoms include various repet-
itive stereotyped behaviors and also defects in communication (verbal and non-verbal) and
reciprocal social interactions [65]. The etiology of ASD is extremely complex, including
both genetic and environmental influences. Studies showed that there were mutations
linked to ASD that could range from single-nucleotide variants to copy number variants
and chromosomal abnormalities that affected both coding and non-coding genes [188].
Because there is a vast heterogeneity of genetic components in ASD, and the brain tissue
of patients cannot be used for clinical diagnostic purposes, this pathology is still being
studied, and the role of lncRNAs is still yet to be fully investigated (Table 2). Several groups
have tried to identify the expression profiles of dysregulated mRNAs and lncRNAs in
peripheral leukocytes from the blood of patients in order to analyze in which pathways
these transcripts are involved [183,189]. The studies confirmed that many dysregulated
lncRNAs were associated with regulatory homeobox-related genes (HOXA and HOXB),
which might have confirmed their important role in ASD pathophysiology. Moreover,
Wang and colleagues [183] suggested that lncRNAs involved in synaptic vesicle trans-
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port/signaling and long-term potentiation and depression play a major role in ASD. The
analysis of post-mortem human brain tissue (prefrontal cortex (PFC) and cerebellum) iden-
tified 222 aberrantly expressed lncRNAs in individuals with ASD compared to the control
group. Moreover, there was relative homogeneity of lncRNA expression between the
PFC and cerebellum in the post-mortem tissue of individuals with ASD compared to the
control [55]. Most of these transcripts were associated with the protein-coding genes that
were expressed throughout neurogenesis and brain development [190–192]. An example is
the gene coding of the ubiquitin protein ligase E3A (UBE3A), which is also disrupted in
Angelman syndrome, which shares some clinical symptoms with ASD [109,170,193–195].
Thirty-eight lncRNAs have been identified as the antisense transcripts to protein-coding
genes already linked with ASD such as SYNGAP1-AS, which is shown to be upregulated
in the post-mortem PFC of individuals with ASD [3,65,196].
Other studies showed that a certain single nucleotide polymorphism in the antisense
transcript to a processed pseudogene of moesin (MSNP1AS) also could be present and
upregulated in some ASD cases [197]. This lncRNA regulates the expression of moesin,
which is an important factor in neurons regulating the immune response and architecture of
the nucleus [3,65,198,199]. Upregulation of MSNP1AS leads to downregulation of moesin
translation, negatively affecting neurite morphology and function [65,170,198,199].
SHANK2-AS, the antisense transcript of SH3 and multiple-ankyrin repeat-domains
protein 2, and BDNF-AS, the antisense to the brain-derived neurotrophic factor, represent
other examples of the antisense lncRNAs associated with ASD (Table 2) [183,200–202].
Most of these identified antisense transcripts were associated with regulatory homeobox-
related genes (HOXA and HOXB), some of whose mRNAs were also found to be aberrantly
expressed.
4.2. Schizophrenia
SZ is a developmental neuropsychiatric disorder affecting up to 1% of the population.
This disease is characterized by positive symptoms such as delusions, hallucinations and
psychosis and negative symptoms such as depression, apathy and dysphoria. The exact
etiology of SZ is not yet known. However, it seems that there are strong influences from
genetics, epigenetics and the environment [65,188,203].
One of the lncRNAs most frequently linked with SZ is the nuclear transcript GOMAFU
(Table 2) [23]. This lncRNA competitively binds to various miRNA and splicing factors,
resulting in the decreased translation of SZ-linked mRNA [49,204]. In SZ post-mortem
brain tissue, it was found that the GOMAFU expression level was significantly lower
compared to the control. This downregulation has a very serious effect because it regulates
splicing factors QKI (quaking homolog) and SRSF1 (serine/arginine-rich splicing factor 1),
with global consequences on alternative splicing (Figure 7) [3,23,50]. It also upregulates
two SZ-linked genes: DISC1 (disrupted in schizophrenia 1) and ERBB4 (v-erb-a erythrob-
lastic leukemia viral oncogene homolog 4) [178,192,205]. GOMAFU knockdown results
in splicing variants of these genes, similar to the ones observed in patients. Interestingly,
the overexpression of GOMAFU in iPSCs resulted in the downregulation of the SZ-related
splice variants of DISC1 and ERBB4. This lncRNA has also been studied in the context
of anxiety-related behavior (also occurring in SZ), as its levels are downregulated in the
medial prefrontal cortex, impacting fear conditioning in mice. Mice with GOMAFU knock-
down additionally present higher anxiety levels and fear-related behavior. While mice
did not present any significant developmental abnormalities, they did present aberrations
in their behavior and “wellbeing”, which might have suggested that even the slightest
impact of GOMAFU function on neurodevelopment could result in significant behavioral
changes [23,50,65,188,192]. Furthermore, GOMAFU takes part in the regulation of many
other processes such as cell proliferation, migration and apoptosis through competitive
interactions with various miRNAs [96,99,192,203].
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Figure 7. GOMAFU (MIAT) involvement in alternative splicing and SZ. When the cell is in an inactive
state, the potassium channels (K+) are closed, and GOMAFU can bind several splicing factors (QKI;
quaking homolog; SF1: splicing factor 1; SRSF1: serine/arginine rich SF1) involved in the expression
of the SZ-related genes. In this way, it functional alternative splicing resulting in the decreased
production of SZ-related proteins. When the cell becomes active, however, the ion channels open,
and the influx of K+ ions leads to GOMAFU transcription downregulation (which is significantly
decreased in SZ). The splicing factors are, therefore, free to act toward the alternative splicing of
SZ-linked genes.
The DISC1-AS lncRNA has been linked to SZ (Table 2), as it negatively regulates
DISC1 expression [65,188,192]. DLG2AS (antisense to discs large homolog 2) dysregulation
has also been found in SZ patients’ brains. Through the control of DLG2 gene expres-
sion (downregulated in the hippocampus of SZ patients), these lncRNAs impact brain
development, long-term synaptic potentiation and axonal guidance signaling [188].
LncRNAs associated with the nuclear factor-κB (NF-κB) protein family have also been
linked with SZ pathophysiology. This protein family has an important role in neurodevel-
opment, interacting with crucial genes/pathways for neurogenesis such as Notch, Shh and
Wnt, and it also regulates inflammatory response [206]. In SZ patients, both NF-κB and
genes that direct its translocation are downregulated, especially in the superior temporal
gyrus. Safa and colleagues [206] showed that the dysregulated levels of lncRNAs associated
with NF-κB could be found in the blood plasma of SZ patients. Most of these transcripts
were upregulated in samples from the SZ group and might have been related to higher
immune activation in the cortical regions. Moreover, most of these lncRNAs along the
NF-κB pathway were involved in neurogenesis, synaptogenesis and brain development;
hence, they may have played a role in the development of various neurological disorders
including SZ [188,192,206].
5. Final Remarks
LncRNAs regulate several processes during brain development, neurogenesis, cell
fate decision, maturation and differentiation [26] and are involved in cognitive mechanisms
and memory formation [26]. Because lncRNAs act at different levels, any variation of
their expression can result in developmental defects and neurological and psychiatric
disorders [52]. One of the challenges in this field is to better understand the mechanisms of
action of lncRNAs, the pathways in which they are involved and the partners with which
they act during development. A more in-depth study of lncRNA and coding genes/genome
architecture relationships could broaden the knowledge on the emerging link between
neurodevelopmental defects and neurodegenerative phenotypes. Furthermore, under-
standing the roles of lncRNA-driven epigenetic modifications is also of pivotal importance
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for tailored treatments. It is therefore extremely necessary to develop adequate genetic
tools and establish animal and in vitro models to study in detail the networks of lncRNAs
and their alterations in disease. To date, only a small percentage of lncRNAs have been
studied in pathological processes. With our review, we aimed to further stimulate lncRNA
research in neurological and neurodevelopmental disorders for a broader understanding
of disease and for implementing novel, RNA-based therapeutic approaches.
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